The University of California, San Diego (UCSD) was awarded a $414,750 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to investigate the role of intestinal gp130 signaling in preventing alcohol-associated liver disease. The proposed research aims to define the gp130-STAT3-Reg3 signaling axis involved in protecting against ethanol-induced liver disease and assess the potential of a novel engineered gp130...
This federal Project Grant award of $698,356.00, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), supports research to characterize alcohol-associated gut dysbiosis and its links to cardiovascular disease (CVD) risk among people with HIV infection. The research, led by Brown University, leverages data and biospecimens from three existing NIAAA-funded studies to investigate how alcohol-induced shifts in gut microbiome...
This National Institute on Alcohol Abuse and Alcoholism (NIAAA) Project Grant award under the Alcohol Research Programs (CFDA 93.273) will support a research study to investigate vascular reactivity and adaptability in relation to alcohol use behaviors, including chronic binge drinking and alcohol/cannabis co-use. The $115,934 award, effective September 1, 2024 through May 31, 2026, will enable the recipient, Rutgers University, to conduct a single-session alcohol administration study that...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, provides $151,869 to support research investigating the relationship between alcohol consumption, metabolic function, and the progression of Alzheimer's disease (AD). The primary objectives of this 2-year project are to: 1) assess the impact of chronic ethanol exposure on metabolic function and tau pathology in an AD mouse model;...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $630,362 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Carnegie Mellon University to study the relationship between close relationships and alcohol use disorder (AUD) risk. The project will examine how poor relationship quality impacts the way couples experience alcohol, which may lead to heavier drinking and increased AUD symptoms over time. The study will involve administering alcohol to 210 couples...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a study titled "Implications of Midlife Alcohol Use for Risk of Dementia in Male and Female Twins: Unique Contributions and Interactions with APOE4". The $468,534 award, with a project period from September 2024 to August 2026, will examine the relationship between midlife alcohol consumption and the risk of Alzheimer's disease and related dementias (ADRD) in over 32,000 male and...
This federal Project Grant award for $469,330 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) aims to investigate the role of the skeletal muscle circadian clock in the development of alcohol-associated muscle disease (AAMD). The research, to be conducted by Florida State University from September 2024 to August 2026, will have two key objectives: Determine whether disruption to the skeletal muscle core molecular clock...
This $235,750 Project Grant award, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to leverage existing human serum samples from longitudinal studies to characterize the effects of alcohol use disorder (AUD) and various treatments on extracellular vesicles (EVs) and their protein/lipid profiles. The goal is to assess the utility of EV-based serum diagnostics for detecting and monitoring alcohol-related white...
This $223,531 federal Project Grant awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a Phase Ia/b proof-of-concept study to evaluate the potential of the FDA-approved drug diclofenac as a novel treatment for alcohol use disorder (AUD). The primary aim is to identify the optimal dose of diclofenac that can modulate the kynurenine pathway, a key metabolic pathway implicated in AUD, by increasing levels of the...
This $328,500 Project Grant was awarded on August 20, 2024 by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program. The grant supports research at Louisiana State University Health Sciences Center-Shreveport to investigate the role of lysophosphatidic acid (LPA) signaling in alcohol-induced blood-brain barrier disruption and neuroinflammation. The research aims to assess the effects of heavy alcohol consumption...